IP Library Granted Patent US 9,561,269
Granted Patent B2
US 9,561,269 · App. 14/604,620 · Granted Feb 7, 2017

Neisseria meningitidis compositions and methods thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,561,269
App. No.
14/604,620
Granted
Feb 7, 2017
Kind
B2
Abstract

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

Claims (12)

1. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 76.

2. The isolated polypeptide according to claim 1 , wherein the polypeptide is lipidated.

3. The isolated polypeptide according to claim 1 , wherein the polypeptide is non-lipidated.

4. The isolated polypeptide according to claim 1 , wherein the polypeptide is immunogenic.

5. An isolated polypeptide comprising the sequence set forth in SEQ ID NO: 76, wherein the cysteine at position 1 is deleted.

6. The isolated polypeptide according to claim 5 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry.

7. An isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 76.

8. The isolated polypeptide according to claim 7 , wherein the polypeptide is lipidated.

9. The isolated polypeptide according to claim 7 , wherein the polypeptide is non-lipidated.

10. The isolated polypeptide according to claim 7 , wherein the polypeptide is immunogenic.

11. An immunogenic composition comprising the polypeptide as in any one of claims 1 - 10 .

12. The composition of claim 11 , further comprising an adjuvant.

Assignments (3)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2016
From: ANDERSON, ANNALIESA SYBIL; HOISETH, SUSAN KAY; JANSEN, KATHRIN UTE; MORAN, JUSTIN KEITH; RUPPEN, MARK E.
To: PFIZER INC.
Reel/Frame 039350/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2015
From: ZLOTNICK, GARY WARREN; BERNFIELD, LIESEL A.; FARLEY, JOHN ERWIN
To: PFIZER INC
Reel/Frame 035012/0481 →